Suramin attenuates dystrophin‐deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy. Issue 6 (11th September 2013)

• Record Type: Journal Article
• Authors: De Oliveira Moreira, Drielen; Pereira, Juliano Alves; Taniguti, Ana Paula Tiemi; Matsumura, Cíntia Yuri; Ramos, Luis Alberto Ferreira; Areas, Miguel Arcanjo; Neto, Humberto Santo; Marques, Maria Julia
• Is Part Of: Muscle & nerve. Volume 48:Issue 6(2013:Dec.)
• Page Start: 911
• Page End: 919
• Publication Date: 2013-09-11
• Subjects: Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.23858
• Languages: English
• ISSNs: 0148-639X

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p> <italic>Introduction</italic>: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in <italic>mdx</italic> mice. <italic>Methods</italic>: <italic>mdx</italic> mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control <italic>mdx</italic> mice (8 months old) were injected with saline. <italic>Results</italic>: Suramin improved the electrocardiography profile with the main corrections seen in S‐ to R‐wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. <italic>Conclusions</italic>: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. <italic>Muscle Nerve</italic><bold>48</bold>: 911–919, 2013</p> </abstract>